This is a type of breast cancer that starts in the milk ducts. It's the most common type of breast cancer. The cancer cells grow into the surrounding breast tissue.
Every report comes from a Lived member, sent anonymously.
Have you had Lumpectomy for Invasive Ductal Carcinoma?
Invasive ductal carcinoma (IDC) is the most common kind of breast cancer, accounting for roughly 70 to 80 percent of cases. It begins in the cells lining the milk ducts, the thin tubes that carry milk toward the nipple, and has grown through the duct wall into the surrounding breast tissue. Once it has done that, it can reach nearby lymph nodes and, in some people, other parts of the body. The word "invasive" is what separates IDC from ductal carcinoma in situ (DCIS), in which abnormal cells stay inside the duct lining. IDC is often found on a screening mammogram before it causes symptoms. When it is felt, it is usually a new lump in the breast or armpit, though it can also show up as skin dimpling, a nipple turning inward or a change in the shape of the breast. IDC is not a single disease with a single treatment. Tests on the tumor sort it into groups that behave differently and respond to different medicines, so two people with IDC can have very different treatment plans and outlooks. It mainly affects women, but men can develop it too.
Breast cancer begins with changes in a cell's DNA that let it grow out of control. For most people, the reason those changes happened cannot be pinned down. A smaller group inherits a gene change that raises risk considerably, most often in the BRCA1 or BRCA2 genes, which also raise the risk of ovarian and some other cancers. Risk rises with age and with a personal history of breast cancer or certain benign breast conditions. Dense breast tissue, earlier radiation to the chest, obesity and drinking alcohol also add risk. So does longer lifetime exposure to estrogen, such as starting periods early, reaching menopause late, having a first child later or not at all, and using menopausal hormone therapy. These factors shift the odds; many people with several of them never develop breast cancer, and many people diagnosed have none.
A suspicious area is usually found on a mammogram or felt as a lump, then examined further with diagnostic mammogram views, ultrasound and sometimes MRI. Imaging can raise strong suspicion, but only a biopsy confirms cancer. A needle removes small samples of tissue, and a pathologist looks at them under a microscope to see whether the cells have broken out of the ducts and how abnormal they look (the grade). The same sample is tested for features that guide treatment. Hormone receptor tests check whether the cancer cells carry receptors for estrogen or progesterone. Results under 1 percent of cells count as negative; above that, hormone therapy is usually offered. About three in four breast cancers have at least one of these receptors. A HER2 test measures a growth-signaling protein called human epidermal growth factor receptor 2. It is reported as a score from 0 to 3+, sometimes clarified with a second test that counts copies of the HER2 gene (FISH); a 3+ score, or a 2+ score confirmed by that gene test, means HER2-positive, which is true of about 15 to 20 percent of breast cancers. A cancer negative on all three is called triple-negative. Staging then describes the tumor's size, whether lymph nodes contain cancer and whether it has spread elsewhere. Lymph nodes are often checked during surgery, and scans are added when there are signs the cancer may have spread. Genetic testing for BRCA1 and BRCA2 is recommended for everyone diagnosed at 65 or younger, and for some older people depending on family history or treatment options, because the result can change treatment and matters for relatives.
When IDC has not spread beyond the breast and nearby lymph nodes (stages I to III), the goal is cure, and treatment usually combines surgery with medicines that travel through the body. Surgery is either a lumpectomy, which removes the tumor with a margin of healthy tissue, or a mastectomy, which removes the whole breast. For early-stage cancers, survival is the same with either choice when lumpectomy is followed by radiation, which lowers the chance of the cancer returning in the breast. A sentinel lymph node biopsy removes the first few nodes the cancer would reach to check for spread. Radiation after mastectomy depends on tumor size and lymph node findings. Breast reconstruction can sometimes be done at the same time as surgery, though it may be delayed when radiation is needed. The tumor's test results decide which medicines help. Hormone receptor-positive cancers are treated with hormone therapy, either tamoxifen or an aromatase inhibitor (a pill that lowers estrogen after menopause, such as anastrozole or letrozole), usually taken for at least five years. HER2-positive cancers are treated with chemotherapy plus HER2-targeted drugs such as trastuzumab (Herceptin), given for up to a year. Triple-negative cancers rely on chemotherapy, often combined with the immunotherapy drug pembrolizumab (Keytruda). Chemotherapy is also used for some hormone receptor-positive cancers; for smaller ones, a gene test on the tumor can show whether it is likely to add benefit. For higher-risk cancers, further targeted pills may be added after surgery. Medicines are often given before surgery, especially for larger, HER2-positive or triple-negative tumors. This can shrink the tumor enough to allow a lumpectomy instead of a mastectomy, and how much cancer remains at surgery helps decide what comes next. When IDC has spread to distant organs such as bones, liver or lungs (stage IV), it is very difficult to cure. Treatment then relies on medicines chosen by the same receptor results, aiming to control the cancer and its symptoms for as long as possible, and many people live for years on treatment. Clinical trials are an option at every stage.
Most IDC is found before it has spread to distant organs, and the outlook at that point is very good. Using a common measure called five-year relative survival, which compares people with cancer to the general population, US figures are above 99 percent when breast cancer is confined to the breast, about 87 percent when it has reached nearby lymph nodes or tissue, and about 32 percent when it has spread to distant parts of the body. These figures cover breast cancer as a whole, reflect people diagnosed several years ago, and cannot predict any one person's course; receptor status, grade, age and response to treatment all matter. Active treatment for early IDC usually takes several months, longer when chemotherapy is given before and after surgery. Common effects include fatigue, hair loss and a raised infection risk with chemotherapy, skin irritation from radiation, and numbness, stiffness or swelling around the surgery. Removing lymph nodes can lead to lymphedema, a long-term swelling of the arm or chest. Hormone therapy often brings hot flashes or joint aches, and aromatase inhibitors can thin the bones, so bone density is checked. Treatment can also affect fertility and sexual health, which is worth raising before it starts. After treatment, follow-up visits are typically every three to six months at first and about once a year after five years. Mammograms continue yearly on any remaining breast tissue, but routine scans and blood tests are not needed for most early-stage cancers. Hormone receptor-positive cancers can come back many years later, which is part of why hormone therapy continues so long; receptor-negative cancers, if they return, tend to do so in the first few years. Staying active, keeping a healthy weight and limiting alcohol may lower the risk of recurrence.
See a clinician about any new breast or armpit lump, skin dimpling, a nipple that turns inward, nipple discharge other than breast milk, red or scaly nipple skin, or swelling of part of the breast, even if a recent mammogram was normal. Most of these changes are not cancer, but each needs to be checked. During chemotherapy, call your care team right away for a fever of 100.5°F (38°C) or higher, chills or other signs of infection, because infections when white blood cell counts are low can be life-threatening. After treatment, contact the team promptly about new symptoms between visits rather than waiting for the next appointment, about any new swelling in the arm or chest, and, if you take tamoxifen and still have a uterus, about any unusual vaginal bleeding or spotting.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Invasive Ductal Carcinoma is like, what's helped you, or ask the community a question.